Tectonic Therapeutic Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alise Reicin
Chief executive officer
US$932.0k
Total compensation
| CEO salary percentage | 61.7% |
| CEO tenure | no data |
| CEO ownership | 2.0% |
| Management average tenure | 2.1yrs |
| Board average tenure | no data |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$932k | US$575k | -US$43m |
Compensation vs Market: Alise's total compensation ($USD931.96K) is below average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Insufficient data to compare Alise's compensation with company performance.
CEO
Alise Reicin (63 yo)
no data
Tenure
US$931,962
Compensation
Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$931.96k | 1.98% $ 4.7m | |
| Chief Medical Officer | 3.1yrs | US$699.78k | 0.22% $ 517.2k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 2.1yrs | no data | 0.073% $ 172.4k | |
| Senior Vice President of People & Culture | 2.1yrs | no data | no data | |
| Chief Development Officer | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data | |
| Senior Vice President of Antibody Engineering & Protein Sciences | no data | no data | no data |
2.1yrs
Average Tenure
53yo
Average Age
Experienced Management: TECX's management team is considered experienced (2.1 years average tenure).